Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAFETERIA: Escalating Thresholds for Reducing Peanut Allergy
NCT03907397Phase 2Completed
- Start
- Aug 2019
- Primary completion
- Nov 2023
- Modality
- Recombinant Proteins and Enzymes, Allergy Immunotherapy
- Countries
- 1
01
Overview
A Phase 2 trial of peanut protein in peanut allergy. Started Aug 2019; status: completed.
02
Drugs
peanut protein
03
Conditions
peanut allergy
Beyond the preview
Go deeper on NCT03907397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03907397.